| abstract |
The present invention relates to compounds of formula (I), wherein R is (A), or phenyl, pyridyl or pyridazinyl, wherein phenyl, pyridyl and pyridazinyl may be optionally substituted by : cyano, lower alkyl, halogen-substituted phenyl, lower alkyl-substituted [1,2,4] Oxadiazol-3-yl or substituted by 2-oxo-piperidin-1-yl; X is NR or O; R is C(O)-lower alkyl, -C(O)-substituted by lower alkyl Cycloalkyl, cycloalkyl, or phenyl, pyridyl or pyridazinyl, wherein phenyl, pyridyl and pyridazinyl may be optionally substituted by lower alkyl, lower alkoxy, cyano -C(O)-lower alkyl, halogen or lower alkyl substituted by halogen; R2 is hydrogen or lower alkyl; R3 is hydrogen, halogen, cyano, lower alkyl or lower alkyl substituted by halogen Alkyl; R 4 is hydrogen or lower alkyl; wherein R 2 and R 4 are not hydrogen or lower alkyl at the same time; R 5 is lower alkyl; R 6 is halogen, hydroxy, lower alkyl, lower alkoxy, lower alkyl, S(O) 2 -lower alkyl or cyano substituted by halogen; or a pharmaceutically acceptable acid addition salt thereof. The compounds of the present invention have been found to be high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD). |